适用 □不适用 通化金马药业集团股份有限公司 2022 年年度报告全文 七、董事会下设专门委员会在报告期内的情况 通化金马药业集团股份有限公司 2022 年年度报告全文 公司计划年度不派发现金红利，不送红股，不以公积金转增股本。 十四、内部控制自我评价报告或内部控制审计报告 十二、报告期内接待调研、沟通、采访等活动 适用 □不适用 | --- | --- | --- | --- | --- | --- | --- | |-----------------------------|----------|----------|--------------|------------|-------------------------------------------------|---------------------| | 接待时间 | 接待地点 | 接待方式 | 接待对象类型 | 接待对象 | 谈论的主要内 容及提供的资 料 | 调研的基本情 况索引 | | 2022 年 01 月 04 日 | 公司 | 电话沟通 | 个人 | 个人投资者 | 公司生产经营 情况。未向投 资者提供任何 资料。 | 不适用 ...

证券代码：000766 证券简称：通化金马 通化金马药业集团股份有限公司投资者关系活动记录表 编号：20180625 | --- | --- | |-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Group 1: Investor Relations Activities - The company participated in the 2021 Jilin Province online collective performance briefing on May 14, 2021 [1] - The event was held on the "Investor Relations Interactive Platform" provided by Shenzhen Panorama Network Co., Ltd. [1] Group 2: Key Questions and Answers - Question about whether the company's drugs will be included in the medical insurance directory this year; the company is monitoring the situation [1][2] - Inquiry regarding the company's plans for share repurchase; currently, there are no plans for share buyback [1][2] - Question about other new drugs in development besides the Amber Dihydroaminoacridine Tablets; the company has two invested drug research institutions [2] - Inquiry about the resolution of the company's debt issues related to the controlling shareholder's equity pledge dispute, which is currently in judicial proceedings [2] - Question regarding the timeline for the new drug launch; the Amber Dihydroaminoacridine Tablets have completed enrollment of 600 cases, with results expected by July or August 2021 [2]

通化金马药业集团股份有限公司 2022 年第三季度报告 □是 否 证券代码：000766 证券简称：通化金马 公告编号：2022-42 通化金马药业集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|--------------------------|-- ...

通化金马药业集团股份有限公司 2022 年半年度报告全文 通化金马药业集团股份有限公司 2022 年半年度报告 2022 年 8 月 1 通化金马药业集团股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主 管人员)耿兰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来计划等前瞻性陈述，该计划不构成公司对投资者 的实质承诺，投资者及相关人士应当对此保持足够的风险认识，并且应当理 解计划、预测与承诺之间的差异。 本公司请投资者认真阅读本半年度报告全文，公司在本报告第三节之 "十、公司面临的风险和应对措施" 部分描述了公司可能面临的风险及应对 措施，敬请广大投资者注意阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2022 年半年度报告全文 目录 | --- | ...

Financial Performance - The company's revenue for Q1 2022 was ¥357,550,409.09, a decrease of 6.64% compared to ¥382,987,117.99 in the same period last year[1] - Net profit attributable to shareholders increased by 42.19% to ¥5,788,129.66 from ¥4,070,763.78 year-on-year[1] - The net profit after deducting non-recurring gains and losses surged by 360.91% to ¥4,263,414.14 compared to ¥924,990.49 in the previous year[1] - Basic and diluted earnings per share rose by 42.86% to ¥0.0060 from ¥0.0042 year-on-year[1] - Total operating revenue for Q1 2022 was CNY 357,550,409.09, a decrease of 6.4% from CNY 382,987,117.99 in Q1 2021[13] - Net profit for Q1 2022 was CNY 5,583,342.14, an increase of 49.5% compared to CNY 3,731,956.70 in Q1 2021[14] Cash Flow - Operating cash flow for the period was ¥6,770,028.14, reflecting a significant increase of 357.11% from ¥1,481,060.68 in the same quarter last year[1] - Operating cash inflow for the current period was ¥306,207,804.95, a decrease of 15.3% from ¥361,364,592.59 in the previous period[16] - Operating cash outflow for the current period was ¥299,437,776.81, down 16.8% from ¥359,883,531.91 in the previous period[16] - Net cash flow from operating activities increased to ¥6,770,028.14, compared to ¥1,481,060.68 in the previous period[16] - Cash flow from investment activities resulted in a net outflow of ¥6,916,875.85, an improvement from a net outflow of ¥10,418,366.92 in the previous period[17] - Cash flow from financing activities showed a net outflow of ¥43,864,360.08, slightly better than the previous period's outflow of ¥44,971,072.19[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,634,838,733.13, a slight decrease of 0.13% from ¥4,640,791,421.63 at the end of the previous year[1] - The company's cash and cash equivalents decreased to approximately RMB 258.43 million from RMB 301.59 million, reflecting a decline of about 14.3%[10] - Accounts receivable increased to approximately RMB 426.97 million, up from RMB 350.61 million, indicating a growth of about 21.7%[10] - Inventory decreased to approximately RMB 367.26 million from RMB 384.58 million, a reduction of about 4.5%[11] - Total liabilities decreased slightly to CNY 2,289,942,938.73 from CNY 2,301,478,969.37 in the previous year[12] - The company’s total liabilities included short-term borrowings of RMB 40 million, remaining stable compared to the previous period[11] Research and Development - The company's R&D expenses increased by 165.57% to ¥8,393,049.09 from ¥3,160,401.87 in the same period last year, indicating a strong focus on innovation[3] - R&D expenses increased significantly to CNY 8,393,049.09, up 165.5% from CNY 3,160,401.87 in the same period last year[13] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,300, with no preferred shareholders[4] - The proportion of shares held by the largest shareholder, Yu Lanjun, increased to 19.66% after the judicial auction of shares held by Beijing Jinshang[9] - The company is facing legal disputes involving its major shareholder, which has resulted in a reduction of shareholding percentage[9] Other Financial Metrics - The weighted average return on net assets was 0.25%, up from 0.18% in the previous year[1] - The company reported a total of 1,149.82 million in current assets, slightly down from 1,151.68 million at the beginning of the year[11] - Long-term equity investments were valued at approximately RMB 55.11 million, a minor decrease from RMB 56.03 million[11] - The company reported a significant reduction in sales expenses to CNY 199,604,097.25, down 13.2% from CNY 230,032,417.37 in the previous year[13] Audit Status - The first quarter report was not audited[18]

Financial Performance - The company's operating revenue for 2021 was ¥1,515,482,473.31, an increase of 36.31% compared to ¥1,111,802,396.45 in 2020[12]. - The net profit attributable to shareholders for 2021 was ¥35,273,252.71, a 109.81% increase from a loss of ¥359,496,105.33 in 2020[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥20,304,105.76, up 104.82% from a loss of ¥421,277,176.76 in 2020[12]. - The net cash flow from operating activities for 2021 was ¥138,329,704.76, representing a 71.40% increase from ¥80,705,132.34 in 2020[12]. - The total assets at the end of 2021 were ¥4,640,791,421.63, a decrease of 6.76% from ¥4,977,076,111.43 at the end of 2020[12]. - The company reported a weighted average return on equity of 1.54% for 2021, compared to -14.62% in 2020[12]. - The company achieved a total revenue of ¥1,515,482,473.31, representing a year-on-year growth of 36.31%[25]. - The net profit attributable to shareholders reached ¥35,273,252.71, marking a significant increase of 109.81% compared to the previous year[24]. - The revenue from traditional Chinese medicine amounted to ¥610,540,935.78, which is 40.29% of total revenue and reflects a growth of 55.31% year-on-year[25]. - The revenue from chemical drugs was ¥900,175,655.09, accounting for 59.40% of total revenue, with a year-on-year increase of 26.24%[25]. Research and Development - The company has focused on talent development, emphasizing a younger and more professional management team to support future growth[24]. - The company has implemented comprehensive quality management practices to ensure compliance with GMP standards across all production processes[24]. - The company’s R&D expenses increased by 26.20% to 63,515,492.26 yuan in 2021[33]. - Research and development (R&D) investment amounted to ¥76,137,717.71, representing a 31.46% increase from ¥57,916,518.70 in the previous year[36]. - The number of R&D personnel decreased by 3.25% to 327, while the proportion of R&D personnel in the total workforce increased to 18.66% from 16.98%[36]. - The company is investing heavily in R&D, with a budget allocation of 10 million yuan for developing new technologies and products in the upcoming year[82]. - The company aims to enhance its R&D capabilities and product portfolio, focusing on the development of Amber Dihydroaminoacridine tablets and accelerating the progress of generic drug research[61]. - The company is conducting Phase III clinical trials for its key R&D project, aiming to develop a treatment for Alzheimer's disease[34]. Operational Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on research, production, and sales of various medical products, including oncology, cardiovascular, and gastrointestinal drugs[20]. - The company has implemented a "production based on sales" model, aligning production plans with sales forecasts and inventory levels to enhance operational efficiency[21]. - The new sales system has led to a significant increase in main business revenue, reflecting the company's adaptation to changes in national drug policies and market trends[21]. - The company has established a comprehensive management mechanism across procurement, production, sales, quality control, and R&D, ensuring high decision-making efficiency[23]. - The management team is experienced and multidisciplinary, ensuring effective strategic planning and execution in a rapidly changing market environment[23]. - The company plans to optimize production quality management and improve supply chain integration to ensure the availability of all sales varieties[61]. - The company has strengthened its internal control systems and cost management to enhance operational efficiency and risk prevention[24]. Market Position and Growth - The company plans to focus on product layout and accelerate technological innovation to enhance market competitiveness in response to industry trends and policy changes[18]. - The company anticipates continued growth in the pharmaceutical market driven by population growth, aging demographics, and increased health awareness[60]. - The company is focused on becoming a comprehensive health manufacturing entity, integrating traditional Chinese medicine, biological drugs, and chemical drugs[60]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the healthcare sector[82]. - A new product line is set to launch in Q2 2022, expected to contribute an additional 5 million yuan in revenue within the first year[82]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2023[116]. - The company provided a positive outlook for 2022, projecting a revenue growth of 25% based on new product launches and market expansion strategies[118]. Governance and Compliance - The company has established a robust internal control system to ensure compliance with financial regulations and effective governance[71]. - The company maintains independent operations and decision-making processes, ensuring no undue influence from major shareholders[67]. - The company has a complete and standardized operational system for research and development, production, and sales of pharmaceutical products, demonstrating its independent market operation capability[71]. - The company has a performance-based compensation policy linked to individual capabilities and performance management[96]. - The company has not engaged in significant related-party transactions with its controlling shareholder or other enterprises under its control[71]. - The company has established an independent personnel management department and a complete personnel management system, ensuring that senior management does not hold positions in the controlling shareholder's enterprises[70]. Environmental Responsibility - The company has committed to environmental protection as a key part of its sustainable development strategy, focusing on reducing energy consumption and enhancing resource efficiency[113]. - The company has successfully passed environmental assessments for its raw material workshop renovation project, ensuring compliance with environmental standards[111]. - The company reported a total COD discharge of 2.41 tons and ammonia nitrogen discharge of 0.026 tons in 2021[107]. - The company achieved a 100% compliance rate for wastewater treatment in 2021, processing a total of 127,831 tons of wastewater with an average COD concentration of 18.19 mg/L and ammonia nitrogen concentration of 0.207 mg/L[109]. - The company has implemented a solid waste management system, effectively handling hazardous waste and other solid waste, with all waste disposed of in compliance with regulations[110]. Shareholder Information - The company plans not to distribute cash dividends, nor issue bonus shares, or increase capital from reserves[2]. - The total number of shares outstanding is 966,494,707, with 26.85% being restricted shares and 73.15% being unrestricted shares[162]. - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., holds 23.91% of the shares, totaling 231,064,944 shares, with a decrease of 10,400 shares during the reporting period[165]. - The company has not issued any new securities during the reporting period[164]. - The company has a cash dividend policy in place, with no adjustments made during the reporting period, and plans to not distribute cash dividends or issue bonus shares[98].

通化金马药业集团股份有限公司 2021 年第三季度报告 1 证券代码：000766 证券简称：通化金马 公告编号：2021-42 通化金马药业集团股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|------------------|----------- ...

通化金马药业集团股份有限公司 2021 年半年度报告全文 通化金马药业集团股份有限公司 2021 年半年度报告 2021 年 08 月 1 通化金马药业集团股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | --- | --- | |----------------------------------------------------------------------|-------| | | | | 本年度报告涉及公司未来发展展望、经营计划等前瞻性陈述，不构成对投 | | | 资者的实质承诺，请投资者认真阅读，注意投资风险。公司可能面临的风险详 | | | 见本报告"第三节管理层讨论与分析"之"十、公司面临的风险和应对措施"。 | | | 公司计划不派发现 ...

通化金马药业集团股份有限公司 2021 年第一季度报告全文 通化金马药业集团股份有限公司 2021 年第一季度报告 2021 年 04 月 1 通化金马药业集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证季度报告中财务报表的真实、准确、完整。 2 通化金马药业集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | | | | | ...